Back to School: How biopharma can reboot drug development. Access exclusive analysis here
The Piscataway, N.J., company was to present data today showing that its PEG-hemoglobin blood substitute can enhance the tumor-killing effect
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury